Submissions received by the Committee

Therapeutic Goods Amendment (Pharmaceutical Transparency) Bill 2013

Submissions received by the Committee

Sub No.

1Abbvie Pty Ltd (PDF 200KB) 
2Assoc Prof Ian Haines (PDF 37KB) Attachment 1(PDF 167KB) Attachment 2(PDF 112KB) Attachment 3(PDF 102KB) Attachment 4(PDF 114KB) Attachment 5(PDF 91KB) 
3Dr Mary Osborn (PDF 65KB) 
4Dr Ken Harvey (PDF 172KB) Attachment 1(PDF 573KB) Attachment 2(PDF 163KB) Attachment 3(PDF 71KB) Attachment 4(PDF 487KB) 
5SANOFI (PDF 494KB) 
6Medical Technology Association of Australia and IVD Australia (PDF 537KB) 
7Australian Medical Association (PDF 91KB) 
8Pfizer Australia (PDF 93KB) 
9Vifor Pharma (PDF 53KB) 
10MSD (PDF 105KB) 
11Amgen Australia Pty Ltd (PDF 537KB) 
12Allergan Australia Pty Ltd (PDF 67KB) 
13Lundbeck Australia Pty Ltd (PDF 107KB) 
14Consumers Health Forum of Australia (PDF 244KB) 
15Janssen-Cilag Pty Ltd (PDF 155KB) 
16Medicines Australia (PDF 563KB) 
17GlaxoSmithKline (PDF 103KB) Attachment 1(PDF 294KB) 
18Merck Serono (PDF 1414KB) 
19Australian Self-Medication Industry Inc (PDF 528KB) Attachment 1(PDF 400KB) 
20GMiA (Generic Medicines Industry Association Pty Ltd) (PDF 119KB) 
201 Supplementary Submission(PDF 158KB) 
21Bristol-Myers Squibb (PDF 59KB) 
22Abbott Australasia Pty Ltd  (PDF 1103KB) 
23University of Sydney (PDF 200KB) 
24Department of Health and Ageing (PDF 719KB) Attachment 1(PDF 20KB) Attachment 2(PDF 162KB) Attachment 3(PDF 233KB) Attachment 4(PDF 376KB) Attachment 5(PDF 152KB) 
246 Supplementary Submission(PDF 169KB) 
25Australian Dental Industry Association (PDF 209KB) 


Additional Information Received

1Opening statement, tabled by Dr Ken Harvey, 29 April 2013(PDF 2224KB) 
2Media article: U.S. sues Novartis over kickbacks, tabled by Dr Ken Harvey, 29 April 2013(PDF 338KB) 
3The Great Pill Push. Tracking the marketing of medicines in Australia, tabled by Dr Ken Harvey, 29 April 2013(PDF 1745KB) 
4Opening statement, tabled by GlaxoSmithKline, 29 April 2013(PDF 700KB) 
5Code of Conduct (edition 17), tabled by Medicines Australia, 29 April 2013(PDF 3622KB) 

Answers to Questions on Notice

1Answer to Question on Notice, GlaxoSmithKline, 29 April 2013 (received 30 April 2013)(PDF 81KB) 
2Answer to Question on Notice, Department of Health and Ageing, 29 April 2013 (received 22 May 2013)(PDF 32KB) 
3Answer to Question on Notice, Department of Health and Ageing, 29 April 2013 (received 22 May 2013)(PDF 38KB) 
4Answer to Question on Notice, Department of Health and Ageing, 29 April 2013 (received 22 May 2013)(PDF 32KB) 

For further information, contact:

Senate Finance and Public Administration Committees
PO Box 6100
Parliament House
Canberra ACT 2600
Australia

Phone:+61 2 6277 3439
Fax:+61 2 6277 5809
Email:fpa.sen@aph.gov.au

Facebook LinkedIn Twitter Add | Email Print
Back to top